Articles tagged "HLA antibodies"

2018 American Transplant Congress
Five-Year Outcomes after Randomized Treatment by Rituximab in Early Acute Antibody-Mediated Rejection in Renal Transplantation: Long Term Outcomes of the RITUX ERAH Study
E. Bailly,¹ G. Blancho,² S. Ville,² E. Morelon,³ J. Bamoulid,⁴ S. Caillard,⁵ V. Chatelet,⁶ P. Malvezzi,⁷ J. Tourret,⁸ V. Vuiblet,⁹ D. Anglicheau,¹⁰ D. Bertrand,¹¹ P. Grimbert,¹² F. Haidar,¹³ M. Hazzan,¹⁴ N. Kamar,¹⁵ P. Merville,¹⁶ C. Mousson,¹⁷ V. Pernin,¹⁸ C. Pouteil-Noble,¹⁹ R. Purgus,²⁰ J. Sayegh,²¹ P. Westeel,²² M. Büchler.¹
¹University Hospital, Tours, France; ²Institut de Transplantation-Urologie-Néphrologie, Nantes, France; ³University Hospital, Lyon Edouard Herriot, France; ⁴University Hospital, Besançon, France; ⁵University Hospital, Strasbourg, France; ⁶University Hospital, Caen, France; ⁷University Hospital, Grenoble, France; ⁸Pitié Salpêtrière Hospital, APHP, Paris, France; ⁹University Hospital, Reims, France; ¹⁰Necker Hospital, APHP, Paris, France; ¹¹University Hospital, Rouen, France; ¹²Mondor Hospital, APHP, Paris, France; ¹³Territorial Hospital, Noumea, France; ¹⁴University Hospital, Lille, France; ¹⁵University Hospital, Toulouse, France; ¹⁶University Hospital, Bordeaux, France; ¹⁷University Hospital, Dijon, France; ¹⁸University Hospital, Montpellier, France; ¹⁹University Hospital, Lyon Sud, France; ²⁰University Hospital, Marseille, France; ²¹University Hospital, Angers, France; ²²University Hospital, Amiens, France.
Background The place of rituximab in the treatment of acute antibody-mediated rejection (ABMR) is still controversial. The French multicenter double-blind, placebo-controlled RITUX ERAH study included…
2018 American Transplant Congress
HLA Eplet Mismatch and Donor Specific Antibodies in Kidney Transplantation
S. Wan,^1,2 S. Angel de Wilde,² B. Rosales,² S. Chadban,^1,2 K. Wyburn.^1,2
¹Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ²Sydney Medical School, University of Sydney, Sydney, Australia.
BACKGROUND: Although HLA matching improves graft survival in kidney transplant recipients (KTx), eplet mismatches provide higher resolution information, and could better predict the development of…
2018 American Transplant Congress
The Impact of Pre-Transplant Donor Specific Antibodies (DSA) on AMR Rates in HIV-Infected Kidney Transplant Recipients Inducted with IL-2 RA
S. Farouk, B. Rollins, V. Delaney, N. Singh, V. Sehgal, R. Kent, M. Menon, R. Shapiro, S. Florman, G. DeBoccardo.
Recanati Miller Transplant Institute, Icahn School of Medicine at Mt. Sinai, New York, NY.
Background: 1-year rejection rates in HIV-infected kidney transplant recipients range from 15-40%, compared to overall rejection rates of 10% in HIV-negative patients. We report the…
2018 American Transplant Congress
Sharing Works; Avoiding Kidney Transplantation to an Unintended Recipient by Precision Virtual Cross Match with Excellent Outcomes
G. Roll,¹ A. Webber,¹ M. Travakol,¹ D. Gae,¹ L. Mayen,² V. Corpuz,¹ J. Roberts,¹ N. Ascher,¹ P. Stock,¹ R. Rajalingam.¹
¹UCSF, San Francisco; ²Donor Network West, San Ramon.
Aim: It was recently estimated that 19.2% of imported kidneys go into an unintended recipient(UR), most commonly due to a positive crossmatch(AJT 2017, 17:2139) so…
2018 American Transplant Congress
Change in Estimated Glomerular Filtration Rate Pre and Post Development of Donor-Specific Antibodies after Kidney Transplantation
B. Ho,¹ S. Montag,^1,2 H. Bhagat,³ K. Atiemo,¹ A. Daud,¹ R. Kang,¹ L. Zhao,^1,2 J. Schwartz,³ D. Ladner.¹
¹Northwestern University Transplant and Outcomes Research Collaborative (NUTORC), Chicago; ²Dept of Preventive Medicine, Northwestern University, Chicago; ³Astellas Pharma Global Development, Inc., Northbrook.
Formation of de novo donor-specific antibodies (dnDSA) against human leukocyte antigens contributes to inferior kidney transplant (KT) outcomes. We assessed the effect of dnDSA on…
2018 American Transplant Congress
Donor-Derived Cell-Free DNA Identifies Antibody-Mediated Rejection with Graft Injury in DSA-Positive Kidney Transplant Recipients
S. Jordan,¹ S. Bunnapradist,² J. Bromberg,³ A. Langone,⁴ D. Hiller,⁵ J. Yee,⁵ J. Sninsky,⁵ R. Woodward,⁵ A. Matas.⁶
¹Cedars-Sinai Medical Center, Los Angeles, CA; ²UCLA, Los Angeles, CA; ³University of Maryland School of Medicine, Baltimore, MD; ⁴Vanerbilt University Medical Center, Nashville, TN; ⁵CareDx, Brisbane, CA; ⁶University of Minnesota School of Medicine, Minneapolis, MN.
Purpose: Donor-derived cell-free DNA (dd-cfDNA) discriminates active rejection in kidney transplant patients. Donor-specific antibodies (DSA) to HLA antigens are associated with risk of antibody-mediated rejection…
2018 American Transplant Congress
Not All HLA Mismatches Are Equal: Determining the Relative De Novo DSA Induction Capacity of HLA Mismatches
V. Jucaud,¹ L. Rebellato,² K. Briley,² A. Maldonado,³ C. Haisch,² P. Bolin,² S. Kendrick,⁴ H. Jones,⁴ K. McLawhorn,⁴ D. Leeser,² M. Everly.¹
¹Terasaki Research Institute, Los Angeles, CA; ²East Carolina University, Greenville, NC; ³Vidant Medical Center, Greenville, NC; ⁴Eastern Nephrology Associates, Greenville, NC.
We studied the immunogenicity, defined as the development of de novo DSA (dnDSA), of HLA-A, -B, -DR and -DQ MM (serological) in a cohort of…
2018 American Transplant Congress
Can We Expect the “Unexpected”?
D. Pinelli, A. Tambur.
Northwestern University, Chicago.
A known, seemingly paradoxical, phenomenon of the HLA system is the high overall degree of homology among different HLA alleles, despite vast polymorphism in the…
2018 American Transplant Congress
A Calculated Panel Reactive Antibody (CPRA) Calculator Supporting Both Allele-Level and Antigen-Level HLA Specificities
L. Gragert,^1,2 E. Kransdorf,³ N. Kaur,¹ M. Maiers,² J. Kobashigawa,³ M. Pando.⁴
¹Tulane University School of Medicine, New Orleans; ²National Marrow Donor Program / Be The Match, Minneapolis; ³Cedars-Sinai Heart Institute, Los Angeles; ⁴Baylor Scott and White, Temple.
Introduction:The number of HLA alleles represented on Luminex assays has increased over time, allowing for improved characterization of anti-HLA antibody specificity. Calculated Panel Reactive Antibody…
2018 American Transplant Congress
The Value of Serum Dilution on DSA Outcome Analysis in Renal Transplantation
W. Huang,¹ L. Rebellato,² K. Briley,² P. Bolin,² S. Kendrick,³ A. Maldonado,⁴ D. Leeser,² C. Haisch,² M. Everly.¹
¹Terasaki Research Institute, Los Angeles, CA; ²East Carolina University, Greenville, NC; ³Eastern Nephrology Associates, Greenville, NC; ⁴Vidant Medical Center, Greenville, NC.
Background: Recently, transplant centers have discussed the potential value of sera dilutions in assessment of donor specific anti-HLA antibodies (DSA). However, to date, no data…